Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib versus placebo plus adjuvant radioactive iodine in differentiated thyroid cancer
2013-000423-14Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing Selumetinib + radioactive iodine with Placebo + radioactive iodine (2 arms). Primary endpoint: Complete remission rate in overall study population. Started Apr 2013; status: completed.
02
Drugs
selumetinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2013-000423-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000423-14.